Podcasts about low dose

In this episode of Drugs N Stuff, we answer your steroid and PED questions covering TRT, Tren, Deca, NPP, gyno prevention, contest prep cycles, growth hormone, and more. We also discuss cycle design, nandrolone, androgen receptor sensitivity, and the practical decisions lifters face when planning their next phase. Plus, Dave shares another chapter of Dave the Fugitive and we answer a wide range of audience questions. 0:00 Support Our Sponsors 1:35 Growth Hormone Banned in China? What It Means 8:30 Are Steroids in Ampules Harder to Counterfeit? 19:30 How to Minimize Gynecomastia Risk 22:00 TRT vs Coming Off Cycle | Androgen Receptor Sensitivity 31:00 When to Add a Second Compound to Testosterone 34:20 Injectable YK-11 Feedback & Experiences 35:15 Low Dose Tren for a Summer Recomp 41:00 NPP vs Deca | Are They Equal Mg for Mg? 44:20 Managing a Bulk & Adding an Oral Compound 47:35 Can Nandrolone Improve Mood? 48:45 Favorite Classic Cars & Modern Cars 54:00 Low Dose Deca with Low Dose Tren 56:10 Standard Contest Prep Steroid Cycles 57:30 Steroid Advice for "Average Gym Bros" vs Competitors 1:02:30 Dave the Fugitive Part 4 UK Blood Work Get your Labs done by Dave in the UK : https://evalbloodanalysis.com/home/ Support the Podcast Patreon — Help keep the show growing. Even $5/month makes a difference. https://www.patreon.com/thinkbigbodybuilding Sponsors TRUE NUTRITION — Custom supplements for serious lifters Use code THINK to save https://www.truenutrition.com/THINK STROM SPORTS — Performance supplements trusted by athletes UK: https://tinyurl.com/ydmbfa54 US: https://stromsportsus.com Supplement Source Canada — Top brand supplements with fast shipping http://www.supplementsource.ca Merch Official THINK BIG Merch — Train, represent, support the brand https://think-big.printify.me/products

Dr. Jason Tucciarone and Dr. Alan Schatzberg (Stanford University, Stanford, CA) join AJP Audio to discuss the use of low-dose buprenorphine as an adjunctive therapy to extend the anti-suicidal effects of ketamine treatment in patients with major depressive disorder and suicidal ideation.  AJP Editor-in-Chief Dr. Ned Kalin joins to discuss the rest of the June issue of the Journal, which takes a close look at issues surrounding suicide and severe depression. 01:20     Tucciarone and Schatzberg interview 03:36     Disparity between effects on suicidal ideation and antidepressant ratings 05:36     Ethics of placebo and ketamine in patients with suicidal ideation 08:28     Immediate clinical implications 11:40     Limitations 14:10     Further research 16:19     Kalin interview 16:24     Tucciarone et al. 20:39     Rovers et al. 24:30     Jelen et al. Transcript Board-certified psychiatrists, if you're seeking meaningful inpatient work with real clinical autonomy, consider becoming the Clinical Director for a 16-bed behavioral health hospital in Fergus Falls or Bemidji, Minnesota. You'll lead a supportive interdisciplinary team, enjoy predictable work-life balance, and have opportunities for teaching and mentorship without RVU pressure or third-party billing. Learn more on APA's Career Center, JobCentral, by searching Direct Care and Treatment – State of Minnesota. Direct Care and Treatment – State of Minnesota:  bit.ly/DCTClinicalDirector Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse articles online. How authors may submit their work. Follow the journals of APA Publishing on Twitter. E-mail us at ajp@psych.org

JCO Editorial Fellow Dr. Yuvanesh Vedaraju and JCO Associate Editor Dr. Kathy Miller discuss the ASCO 2026 Simultaneous Publication paper "Low-Dose Tamoxifen in Non-Invasive Breast Neoplasia: Long-Term Results from an Individual Participant Data Pooled Analysis." LINK TO FULL TRANSCRIPT  

Full article: Artificial Intelligence–Assisted Lung Nodule Evaluation on Low-Dose Chest CT in Asymptomatic Individuals: A Prospective Randomized Controlled Trial Pragmatic data obtained in clinical settings can add further insights into how AI shapes radiology practice. Hira Qureshi, MD, discusses the AJR article by Hwang et al. that reports a prospective randomized trial of the impact of AI for low-dose chest CT interpretation.

Show notes at pharmacyjoe.com/episode1129 In this episode, I’ll discuss the incidence of torsades from low-dose ondansetron in perioperative patients.

Watch Here : https://www.youtube.com/watch?v=F5G6lxmNrf0 Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve

On this episode of The Vitamin Professor Podcast, Professor Gene Bruno talks to Suresh Lakshmikanthan, PhD, BPharm at Natural Remedies.Suresh Lakshmikanthan, PhD, BPharm, chief business officer at Natural Remedies, leads global business strategy and operations across the company's pharmaceutical and nutraceutical divisions. With more than two decades of international experience, he is focused on advancing innovation and sustainable practices in botanical product development and commercialization.Lakshmikanthan holds a PhD in international business and leadership and an MBA in international business from Walden University, Minneapolis, MN. He earned his Bachelor of Pharmacy from Dr. M.G.R. Medical University, India. He has authored multiple research papers on international business and leadership, and his work continues to shape the intersection of global business strategy and botanical scienceThis podcast is brought to you in partnership with VRM Media and Nutraland USA, Inc. For more information about our host and guest, please see the below information.naturalremedieshumanhealth.com/ashwa-30/⁠https://nutralandusa.com/⁠linkedin.com/in/gene-bruno-ms-mhs-rh-ahg-2ab0508/⁠https://www.vrmmedia.com⁠@hnvirtual, #hnvirtual, #naturalremedies, #genebruno, #thevitaminprofessor, #ashwa-30Find our podcast on your favorite platform:podcasts.apple.com/us/podcast/the-vitamin-professor-podcast/id1746137375youtube.com/channel/UCxeQ-IuqCRmq0YLc7jQNMKAmusic.amazon.com/podcasts/a8a96593-b93c-48cf-9fe9-2891c4035dad/the-vitamin-professor-podcastiheart.com/podcast/269-the-vitamin-professor-podc-175888136/

Best steroid cycles for average gym bros in 2026—what's changed with gear availability and smarter dosing strategies. Dave Crosland & Scott McNally break down TRT-based cycles, orals, estrogen control, and real-world Q&A. If you want practical bodybuilding advice without the BS, this is it. 0:00 Best Steroid Cycle Ratios: Masteron vs Primobolan with Testosterone 0:40 Sponsor Message – Support the Show 1:30 Best Steroid Cycles for Average Gym Bros (2026 Update) 6:15 Equipoise Cycles: Low Testosterone and Estrogen Control Explained 10:30 Oral Steroids in Cycles: When and How to Use Them 15:20 TRT + Anadrol vs Higher Testosterone: Which Works Better? 17:25 Quick Life Update: Dave's Car Problems 17:50 TRT Plus Cycle Ratios: How to Structure Low Dose Stacks 20:00 Sublingual Orals: Faster Absorption and Real Effects 28:00 Fat Loss Cycles: Compounds for an Aggressive 60 lb Cut 32:40 MK-677 Explained: Is It Worth Using? 35:30 Anastrozole Side Effects: What to Watch Out For 37:45 Testosterone Dosing for Amateur Bodybuilders 43:10 Listener Comment: Postal Carrier Question 44:30 Blood Donation on Steroids: Is It Safe or Ethical? 46:10 Cycle Critique: Testosterone, NPP, Trenbolone Stack 48:10 Deca vs NPP: Stacking Strategies Explained 50:20 HCG Use: When It Makes Sense + TRT Applications 54:00 Real Talk: De-escalating Confrontations as a Bigger Guy 59:15 Stories from Dave's Time as a Bouncer 1:16:15 Behind the Scenes: Podcast Banter & Wrap-Up UK Blood Work Get your Labs done by Dave in the UK : https://evalbloodanalysis.com/home/ Support the Podcast Patreon — Help keep the show growing. Even $5/month makes a difference. https://www.patreon.com/thinkbigbodybuilding Sponsors TRUE NUTRITION — Custom supplements for serious lifters Use code THINK to save https://www.truenutrition.com/THINK STROM SPORTS — Performance supplements trusted by athletes UK: https://tinyurl.com/ydmbfa54 US: https://stromsportsus.com Supplement Source Canada — Top brand supplements with fast shipping http://www.supplementsource.ca Merch Official THINK BIG Merch — Train, represent, support the brand https://think-big.printify.me/products Merch Official THINK BIG Merch — Train, represent, support the brand https://think-big.printify.me/products

Send us Fan MailDr. Parvesh Garg, neonatologist and researcher specializing in necrotizing enterocolitis (NEC) and acute kidney injury (AKI) in preterm infants, shares more than a decade of work on two of the most understudied organ systems in the NICU. He explains why surgical NEC is an independent risk factor for long-term neurodevelopmental impairment, how aggressively managing hypotension at the time of diagnosis may protect both the brain and the kidneys, and why the severity of NEC-associated AKI should be used as a prognostic tool in counseling families. He also presents early but fascinating laboratory findings suggesting that low-dose dexamethasone — unlike high doses — may help limit intestinal epithelial loss once NEC has set in, drawing a parallel to what therapeutic hypothermia does for HIE: the event has happened, but the inflammatory cascade may still be containable.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Watch Here : https://www.youtube.com/watch?v=YvyImqE9Ooo Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve

LBCT: Effect Of Low-dose Dobutamine Infusion On N-terminal Pro B-type Natriuretic Peptide In Risk Patients With Acute Myocardial Infarction (DOBERMANN-D) - A Randomized Clinical Trial

In episode 532 I chat with Dr Sorcha O'Connor. Sorcha is a neuroscientist and PhD graduate from Imperial College London, where she led the PsilOCD study investigating low-dose psilocybin for OCD.  We discuss Sorcha's background that led her to this work, what is psilocybin, the background to the study, what the actual study looked like for participants, the outcomes of the study, what's happening in the brain during a dose of psilocybin, future studies, how psychedelics may improve learning, integration sessions with a therapist, what people with OCD can take from this study, limitations of the study, and much more. Hope it helps. Show notes: https://theocdstories.com/episode/sorcha-532 The podcast is made possible by NOCD. NOCD offers effective, convenient therapy available in the US and outside the US. To find out more about NOCD, their therapy plans and if they currently take your insurance head over to https://go.treatmyocd.com/theocdstories Join many other listeners getting our weekly emails. Never miss a podcast episode or update: https://theocdstories.com/newsletter 

Lisa kennt Power-Extreme: Zu viel. Zu wenig. Selten genau richtig. Ihr Akku macht, was er will. Fehlt Disziplin oder ein Spurenelement? In dieser Podcast-Episode bewegen sich zwei Apothekerinnen und eine Frauenärztin zwischen Medizin, Schweizer Lithium-Kurbädern und dem globalen Rohstoff der Zukunft. Und irgendwo dazwischen: Lisa, die einfach nur wieder aufgeladen sein will. Villa Margarita: Lieber voller Energie als nur im Batteriesparmodus.

In this episode, Michelle Weiner, DO, MPH returns to share her expertise on low-dose ketamine for chronic pain. Dr. Weiner is double board-certified in Interventional Pain Medicine, Physical Medicine, and Rehabilitation. She is founder of Neuropain Health delivering personalized integrative care treating the root cause of pain and suffering, both physical and emotional, using a multidisciplinary biopsychosocial approach with many years of clinical experience with ketamine-assisted therapy. In this conversation, Dr. Weiner reframes chronic pain as more than a symptom of tissue damage, describing it instead as a complex sensory and emotional experience shaped by the brain, nervous system, and a person's broader life context. She explains how chronic pain can become entrenched through maladaptive neural network patterns, fear, stress, and identity-level beliefs, and argues that effective treatment must move beyond symptom suppression toward a biopsychosocial model that addresses suffering, function, and quality of life. Drawing on her clinical work, Dr. Weiner discusses how low-dose ketamine, when paired with preparation, integration, pain reprocessing therapy, somatic work, and functional movement, may help create a window of neuroplasticity that allows patients to interrupt rigid pain patterns and reconnect with their own capacity for healing.   In this episode, you'll hear: How Dr. Weiner understands chronic pain The "triple network model" of neuropsychiatric conditions and how Dr. Weiner applies this to thinking about chronic pain Why imaging, injections, and medications often fall short once pain has become chronic and centrally mediated The gate control theory of pain and how this relates to possible mechanisms of ketamine treatments of pain How ketamine may support chronic pain treatment by creating a temporary window of neuroplasticity that can be used for deeper therapeutic change What pain reprocessing therapy is and why Dr. Weiner sees it as a first-line intervention for many chronic pain conditions Patient stories from Dr. Weiner's practice where belief change was a key component of healing pain   Quotes: "Over time, when [pain] becomes chronic, it's no longer trying to alter the physical body, it's actually trying to reprocess what's happening in the brain." [3:47] "Ketamine for me started to become more interesting because I realized that this wind-up phenomenon that is so responsible for a lot of people's chronic pain can actually start to be reversed when we start using medications [like ketamine] that can change the balance of glutamate and GABA [neurotransmitters]." [14:26] "So I just started to think, how can we use the lowest dose of ketamine to create neuroplasticity, guide them in a way that they're able to move and shift the story, and then that's how you can create long term change.  [18:51]  "The key is to understand that we are our own healers. If we're not involved in actively participating in our treatment, then we're relying on someone else outside of us and that's not really a long term plan." [29:20] "More with ketamine is definitely not better. When people feel so disconnected and so separate from themselves, they can experience more fear. And I think that's important to have that sweet spot where they're able to get that time out. They're not really feeling their pain, they're not in their ordinary mind and their conscious thoughts and they're able to have the brain connect in a different way and experience things differently, which then creates hope and allows them to really wake up and say, 'oh, there there are other options out here for me.'" [30:11]   Links: Dr. Weiner's recent article "Treating chronic pain with low dose ketamine and adjunct therapies within a biopsychosocial approach: a case series" Dr. Weiner's website: Neuropain Health Dr. Weiner on Instagram Dr. Weiner on LinkedIn Previous episode: Ketamine-Assisted Psychotherapy for Chronic Pain with Michelle Weiner, DO, MPH Psychedelic Medicine Association Porangui

In this episode of the Full of Beans Podcast, I'm joined by Professor Hubertus Himmerich, Consultant Psychiatrist and Reader in Eating Disorders at King's College London, and the principal investigator of the EDEN study.The EDEN study is the first study of its kind exploring whether low-dose oral ketamine, compared with placebo, could support people living with both anorexia nervosa and major depressive disorder.Depression affects around 50% of people with anorexia, and when low mood, anxiety and hopelessness are present, it can make recovery feel incredibly difficult. Traditional antidepressants often don't work well for people with anorexia, which is why researchers are exploring new approaches.What We Cover in This EpisodeWhy is depression so common in anorexia nervosaWhy SSRIs often don't work well in this populationThe science behind ketamine and how it affects brain plasticityWhy the EDEN study focuses on improving mood rather than weightHow depression can reduce hope and motivation in recoveryThe difference between medical ketamine treatment and recreational ketamine useHow the study has been shaped by people with lived experienceWhy new treatment approaches needed in the eating disorder fieldIf you're interested in taking part in the EDEN study, the team are currently recruiting participants! Please email eden@kcl.ac.uk to find out more!Connect with Us:Subscribe to the Full of Beans PodcastFollow Full of Beans on InstagramCheck out our websiteListen on YouTube⚠️ Content Note: This episode includes discussion of eating disorders, depression, ketamine use and mental health treatment.. Please take care when listening.If you enjoyed this episode, don't forget to subscribe, rate, and share to help us spread awareness.Sending positive beans your way, Han

Send a text

Continuing with her theme of nutrient profiles, on this episode Karolyn talks with mental health expert Peter Bongiorno, ND, about low-dose lithium. How much do you know about this unique, specialized nutrient? What is it used for and how safe is it? Tune in to find out more. In addition to his clinical practice, Dr. Bongiorno is the author of several best-selling books and he is on a mission to revolutionize psychiatric care in this country.Five To Thrive Live is broadcast live Tuesdays at 7PM ET and Music on W4CS Radio – The Cancer Support Network (www.w4cy.com) part of Talk 4 Radio (www.talk4radio.com) on the Talk 4 Media Network (www.talk4media.com).Five To Thrive Live Podcast is also available on Talk 4 Media (www.talk4media.com), Talk 4 Podcasting (www.talk4podcasting.com), iHeartRadio, Amazon Music, Pandora, Spotify, Audible, and over 100 other podcast outlets.

Light smoking is not harmless.

Did you know optimized sleep can transform your days by: ✅ Processing emotions & repairing your body overnight ✅ Waking up energized & clear-headed (no grogginess) ✅ Reducing stress, anxiety & evening wine cravings ✅ Supporting mood, hormones & long-term vitality In this episode, I sit down with Joseph Sheehey, former NASA engineer & founder of Cured Nutrition, to unpack cannabinoids for better rest. We clarify CBD, CBN, microdose THC, full-spectrum hemp — and why quality + herbal synergy make all the difference. Key highlights: Why sleep is essential for emotional processing, recovery & vibrant energy. CBD for calm, CBN for deep "weighted blanket" relaxation, microdose THC for gentle relief without impairment. How Cured's adaptogen-blended gummies outperform typical dispensary options (no paranoia, restored mornings). Joe's journey from depression & near-suicide to building a natural healing brand. The 2025 hemp regulation changes & what they mean for wellness-focused products. Ready for deeper, more restorative sleep? Visit HayleyHobson.com/cured — use code HAYLEY for 15% off (details in show notes). Resources: Shop & discount: HayleyHobson.com/cured (code: HAYLEY) Advocacy info: NCRCA.us Full transcript: Hayley Hobson's Podcast Connect: Instagram • Facebook • TikTok — subscribe for weekly tools to a 10/10 life. Share this with anyone struggling with sleep — and leave a review to help more women find it!

Dr. Monty Pal and Dr. Atul Batra discuss the PLANeT study from India, which evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer, and its place among a growing body of international research on improving efficacy while reducing costs and toxicity with lower doses of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center, Los Angeles. My guest today, I think, is going to be a really riveting one. It's Dr. Atul Batra, who is an additional professor of medical oncology at the All India Institute of Medical Sciences, or AIIMS, in New Delhi. And he's also the senior author of the PLANeT study. It's a very compelling study that evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer. And it's really a big part of a growing body of research that's showing balanced efficacy when we use lower doses of immunotherapy instead of standard doses to reduce cost, as well as potentially toxicity. I think this has huge implications for our global audience, and I'm so thrilled to have you on the podcast today, Dr. Atul Batra, welcome. Dr. Atul Batra: Thank you, Dr. Pal. Dr. Monty Pal: And we'll just take it with first names from here since we're both friends. I have to give the audience some context. Atul, I had the great honor of visiting AIIMS New Delhi. For those that don't know, this is really, you know, the Harvard Medical School of India. It's the most competitive institution for medical training. And on the back end of that, there's also incredible resources when it comes to clinical trials and infrastructure. I just wanted to have you give the audience sort of a scope of the types of trials that you've been able to do at AIIMS New Delhi. Dr. Atul Batra: Thank you, Monty. So, I work at the All India Institute of Medical Sciences, and we had the honor and pleasure of having Monty here this month. And people are still in awe of his lectures that he delivered there. Coming back to our institute, so it's kind of a medical college. It's one of the oldest ones, it was built in 1956. We are lucky enough that we get the best of the residents and fellows because they have to go through an exam, a competitive exam, and mostly it's them who come to us and we're able to do some good work out here. Regarding the trials that we have conducted, we do conduct some investigator-initiated studies, and we try to answer the questions where we can help our own patients. Like, for example, this PLANeT study. Every other patient in the clinic was almost not able to afford Keytruda at the full dose, pembrolizumab, and we had a lot of evidence creeping in that a lower dose might be helpful. And that's how we planned this study. Before that, there are certain cancers that are peculiar to India, like gallbladder cancer, head and neck cancers. These are much more common in India as compared to the U.S., and there are some good studies that have been conducted from our own institute by our senior colleagues which have been presented at ASCO and published in the JCO. We also did the capecitabine hand-foot syndrome study that was known as the D-ToRCH study: 1% diclofenac gel that became the standard of care to prevent hand-foot syndrome.  So, that's kind of a brief overview of investigator-initiated studies. India is slowly and steadily becoming a partner of the global registration trials. And it's more recently, the last five years or so, we have seen that the number of phase 2 and phase 3 trials are increasing and we are able to offer now these trials as well to our patients. Dr. Monty Pal: That was a terrific overview. I just want to highlight for the audience, as we go through some of your discussions today around specific trials, the speed at which this can be done. Just for context, for me to accrue a clinical trial of 30 patients – I think many people have probably come across some of the work that I've done in the microbiome space – at a single institution, 30 patients, right, takes me about a year and a half, two years. We're going to go through some trials today where Dr. Batra and his team have actually, in fact, accrued close to 200 patients over a span of just a year, which is just remarkable by, I would say, any American standard. So, I see a real need for partnership and Atul, I'll kind of get back to that at the end. But without further ado, the focus of this podcast today, I think, is really this terrific presentation you gave in an oral session at ESMO and subsequently published in Annals of Oncology related to the PLANeT study. Would you give the listeners some context around what the study entailed and population and so forth? Dr. Atul Batra: So, we know the KEYNOTE-522 became the standard of care for triple-negative breast cancer, where Keytruda, when added at 200 mg, the standard dose every three weeks with neoadjuvant, increases the pCR from around 51% to 64% by a magnitude of around 13%. However, in India and other low-middle income countries, less than 5% of the patients actually have access to this dose of pembrolizumab. So, our standard of care was actually just chemotherapy till now. And this kind of led us to design this trial. There are data that come from previous trials conducted in India, from the Tata Memorial, done in head and neck space, some other studies done in Hodgkin's lymphoma, that a much lower dose, probably around one-tenth of the dose, works well in these cancers. So, that's where we designed the PLANeT study, where we gave the standard neoadjuvant chemotherapy in the control arm, and in the experimental arm we added 50 mg of pembrolizumab. This was given every six weeks for three doses. So, that's a total of 150 mg over the neoadjuvant period as compared to 1,600 mg that was given in the KEYNOTE-522 study. So, this was almost one-tenth of the study. Dr. Monty Pal: So, a tenth of the dose, which is just remarkable. I mean, that's just such an interesting concept. Dr. Atul Batra: And the results, when we – the primary outcome, this was a phase 2 study. We just wanted to see, is there a signal of activity? And to even our surprise, when we looked at the pathological complete response rates, in the control arm this was 40.5%, and in the experimental arm this was 53.8%. So, a difference came to around 13.3%; it was numerically, I mean, so much similar to what KEYNOTE-522 had with just these many doses. So, this was around 160 patients randomized over one year. We could randomize them in one year because of the load that we see. And the primary endpoint was met, and we could see that the path complete response did show a remarkable increase. We are still following these patients to see whether there is a difference in event-free survival at a longer follow-up. Until now, it's a small follow-up, so the number of events absolute, are different: four events in the experimental arm and 11 events in the control arm. So, we are seeing some signal even in this much short follow-up period as well. But we need to see more of what happens in the longer term. Dr. Monty Pal: That's so impressive. I wonder, with this lower dose, do you attenuate toxicity at all as far as you can gather? Dr. Atul Batra: So, although we shouldn't be doing kind of cross-trial comparisons, but if you look at thyroid dysfunction, we saw that around 10% of our patients had this thyroid dysfunction. This was compared to 15% in the KEYNOTE-522, that was a larger sample size though. But we're seeing that all the toxicities are somewhat less as compared to those in the standard dose. So, the exposure is less, but I mean, I can't really commit definitely on this. For this we would need much more data to say this with more confidence. Dr. Monty Pal: Yeah. I'm going to ask you a really tough question to follow up, and this is probably something that's on everyone's mind after reading a study like this. Is this something that is disease-specific that needs to be replicated across other histologies? The reason I ask this is, you know, you think about paradigms like, for instance, in the States we're toying between intravenous versus subcutaneous delivery of checkpoint inhibitors, and we have studies focused in specific histologies that might justify use across all histologies. With this particular phenomenon, do you think we need to do dedicated studies in renal cell or in colon cancer and other places where, you know, in selected settings we might use checkpoint inhibitors and then decide whether or not there's this dose equivalence, if you will? Dr. Atul Batra: That's a real tough one, though. But I'm happy to share that there are several ongoing studies within India currently. At our institute, my colleagues are leading studies in lung cancer space, cervical cancer. There was already a publication from Tata Memorial Hospital in head and neck cancers and we see that the signal has been consistent throughout. Regarding renal cancer, there was one study that was presented for sure at ASCO from CMC Vellore, that's again a center in South India. That was in RCC at a much lower dose. And for patients who cannot take the full dose, we actually are offering lower dose nivolumab in such patients and we are seeing responses. I mean, we haven't done those randomized trials again because the numbers are much lower in kidney cancers, we know. We could do this trial in triple-negative ones because we had support and we had numbers to conduct this trial. But I'm sure this should be a class effect. I mean, when we can get tumor-agnostic approvals, then some real-world data has come up in almost all tumors, we have seen that consistent effect across tumors. And as we speak of today, I'm also delighted to share that in India, yesterday, we had the first biosimilar of nivolumab and that's now available at a much, much lower price than the original patent product. There was a long ongoing lawsuit that was there, that's over now, and from yesterday onwards, I'm so happy to share here that we would have the first biosimilar of nivolumab that's available. That's going to bring the cost to almost like one-tenth already. Dr. Monty Pal: Wow. That's huge.  I'm going to be very selfish here for a second and focus on a study that is in the renal cell space that your group has done. You know, when it came out, I was really sort of intrigued by this study as well and it reflects sort of a different capability, I think, of AIIMS New Delhi, and that's in the, what I'm going to call, biomarker space. This, for the audience, was a prospective effort to characterize germline variants in patients with advanced kidney cancer. And it's something that we talk about a lot in the kidney cancer literature, whether or not we're missing a lot of these so-called hereditary patterns of RCC. Can you tell us a little bit about that study too? Dr. Atul Batra: Yeah, so that was led by one of our fellows, Chitrakshi Nagpal, and she's just completed her fellowship. And two years back we published that. So, that was done in almost 160 consecutive patients that we recruited over the span of just one year and we saw, apart from the common known mutations in RCC, that was around 5% or so, but a lot of other mutations were also seen that we don't generally see in kidney cancers and we see in other cancers like BRCA1, BRCA2 and others. We are still, I mean, doing those analyses to see whether we get more things out of there in the somatic: is there a loss of heterozygosity or was it just present and in there? Dr. Monty Pal: I thought it was a terrific study and again, I was just so blown away at the pace. I mean, as I look at 140 patients accrued over a span of one year, this is something that would take us perhaps three times as long at City of Hope, and that's with a very sort of, what I consider to be large and dedicated kidney cancer program. So, it really underscores, I think, the need for collaboration. And ever since I came back from my visit to you at AIIMS Delhi, I think I've just been sort of transformed in the sense of trying to think of better ways for us to collaborate. One tangible thing that I'm going to get cracking on is seeing whether or not perhaps we can form some partnerships through SWOG or what we call the NCTN, the National Clinical Trials Network here within the U.S. Talk to me about collaboration. I mean, you've been really terrific at this. How do you sort of envision collaboration enhancing the global landscape of oncology? Dr. Atul Batra: That's really amazing, Monty. That's what we need. We have the infrastructure, we have the manpower, we have patients. I mean, these are all high-volume centers. Unfortunately, we are a little less in numbers, so we are more clinically occupied as well. So, sometimes it's kind of tougher, but again, when it comes to helping out the patients, global collaboration, we need to kind of take you guys along with us and have our patients finish trials earlier. This is a win-win situation for patients, one, because they also get exposure or an option to participate in the clinical trials, and second, we can answer all these scientific questions that we have at a much faster pace. All those things can be done within a much shorter span of time for sure. We are so happy to hear that, and with open hands we are ready to collaborate for all these efforts. Dr. Monty Pal: That's awesome. You know, I came back thinking, gosh, this would be so ideal for some of these rare subtypes of kidney cancer. Prospective clinical trials that I'm running in that space where really we're threatened with closure all the time. And if we just sort of extended a hand to, you know, our partners in India and other countries, you know, I'm sure we could get this research done in a meaningful way and that's got to be a win for patients. Atul, I had such a terrific time chatting with you today. I'm looking forward to seeing lots more productivity from your group there. By the way, for our viewership here, take a look and see what AIIMS New Delhi is doing under the leadership of Dr. Batra and others. It is just a real powerhouse and I think that after doing so, you'll be enticed to collaborate as well.  I'm hoping this is the first of many times that we have you on the podcast. Thank you so much for joining. Dr. Atul Batra: Thank you so much for having me here, Monty. It was a pleasure as always speaking to you. And thank you again. Dr. Monty Pal: You got it.  Well, and thanks to our listeners. I encourage you to check out Dr. Batra's paper. We'll actually have a link to the study in the transcript of this episode.  Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:     Dr. Monty Pal   @montypal Dr. Atul Batra @batraatulonc Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Atul Batra: Stock and Other Ownership Interests: Zydus Pharmaceuticals, Glenmark, Caplin Point Laboratories, Laurus Research Funding: AstraZeneca, Astellas Pharma, Alkem Laboratories

What makes methylene blue so different from most nootropics is how little it takes to have an effect. In this clip, Mark Sloan explains why ultra-low doses of methylene blue can support mental clarity, calm energy, and mitochondrial performance without overstimulation. You'll hear why: Just a few milligrams can support steady, all-day focus Low doses reduce risk while increasing safety and accessibility Methylene blue supports mitochondrial energy production at the cellular level It plays a role in the NAD to NADH ratio, a key marker of metabolic health The brain benefits disproportionately due to high energy demand Tune in to Episode 68, where we go deeper into methylene blue, mitochondria, metabolic health, and why low-dose strategies often outperform aggressive protocols. Links Watch it on YouTube: https://youtu.be/q5PBJJAypDQ Full episode : https://outliyr.com/68 Connect with Nick on social media Instagram Twitter (X) YouTube LinkedIn Easy ways to support Subscribe Leave an Apple Podcast review Suggest a guest Do you have questions, thoughts, or feedback for us? Let me know in the show notes above and one of us will get back to you! Be an Outliyr, Nick  

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

Are allergies silently draining your energy, wearing down your immune system, and keeping you stuck in a cycle of chronic symptoms? Allergies aren't just seasonal annoyances, they are abnormal immune reactions to everyday substances like pollens, molds, dust mites, animal dander, and even foods. When your body misidentifies these normal particles as threats, it triggers inflammation, congestion, infections, fatigue, skin issues, and respiratory problems that can worsen over time. Many people turn to antihistamines, decongestants, or steroids, but these only mask symptoms rather than address the root cause. In this episode, Dr. Hotze breaks down how allergies develop, why they tend to run in families, and how repeated exposure can overwhelm your immune system and lead to the “cycle of illness.” He also explains why antibiotics often exacerbate the problem by disrupting gut flora and fueling yeast overgrowth, which further weakens immunity. Most importantly, Dr. Hotze shares a proven, practical solution called low-dose immunotherapy, a targeted approach that helps block allergic reactions at the source. This therapy can dramatically reduce symptoms, including asthma, sinus infections, eczema, and chronic drainage, by retraining the immune system instead of suppressing it. If allergies are affecting your daily life, your mood, your sleep, or your overall well-being, there is a natural and effective way to restore your health. Low-dose immunotherapy may be the long-term relief you've been searching for. Watch now and subscribe to our podcasts at www.HotzePodcast.com. To receive a FREE copy of Dr. Hotze's best-selling book, “Hormones, Health, and Happiness,” call 281-698-8698 and mention this podcast. Includes free shipping!

The topic of low-dose atropine, not FDA-approved, has become one of the most important conversations in pediatric eye care this year, especially as clinicians turn to the STAR Study for clarity on atropine's role in modern myopia control. The STAR Study is the largest and most ethnically diverse atropine study to date, evaluating 0.01% and 0.03% atropine versus placebo in more than 800 children across three countries.

Watch Here : https://www.youtube.com/watch?v=yJaFlYKLDUs Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve

Watch Here : https://www.youtube.com/watch?v=oaqSZlgDtlY Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve

I'm reposting episodes that were taken down from Spotify. This is a repost of the 2023 conversation. Keith sits down with Itarya Rosenberg to discuss growing up in Bucks County, discovering the local scene, our early show-going experiences, navigating depression and institutions in his high school years and Itarya's early work in Legendary Divorce. We also discuss the formation of Low Dose, the band's history, the end of Low Dose and the beginning of Rid of Me, the band's history, their latest LP "Access to the Lonely", addiction, alcoholism, mental health and more.  Artist Spotlight: Keith speaks to Tristan D'Graves from Incendiary Device about their new self titled LP on Bridge Nine Records  Intro: 0:00 - 6:39 Rid of Me Interview: 6:40 - 1:00:37 Incendiary Device Interview: 1:00:50 - 1:24:11 Outro:  1:24:25 - 1:29:08

In this video, I share my personal experience with low-dose radiation therapy for osteoarthritis and inflammatory knee pain — a treatment with a long history in Europe that's now being re-examined in the U.S. as a safe, evidence-based option for chronic orthopedic pain. Low-dose radiation therapy (LDRT) involves the use of very small, precisely targeted doses of radiation — typically one-tenth or less of what's used in cancer treatment — to reduce inflammation and modulate immune response in joints, tendons, and soft tissues. Research has shown that these low doses can help relieve pain and improve mobility, often providing durable results without the side effects of steroids or long-term medications. I'm joined by Dr. Sanjay Mehta, Radiation Oncologist at St. Joseph Cancer Center in Houston, to discuss the science behind this therapy, its mechanisms of action, and the clinical outcomes we're seeing today for conditions such as: • Osteoarthritis • inflammatory knee pain • Plantar fasciitis • Tennis elbow • Shoulder and joint pain You'll also see a glimpse of my own treatment session, as we explore how this “old yet new” approach is helping patients regain comfort, function, and quality of life — without medications or surgery. Resources: Dr. Sanjay Mehta, Radiation Oncologist St. Joseph Cancer Center https://drsanjaymehta.com/

Today's episode is one I've really been looking forward to because we're diving into something that's transforming the way we think about mental health treatment: low-dose ketamine therapy. My guest, Dr. Sharon Niv, is the co-founder of Joyous, a public benefit company helping make this kind of care more accessible and affordable than ever before. Sharon brings a fascinating background in cognitive psychology, meditation, and technology, and she's helping bridge the gap between neuroscience and therapy in a way that's incredibly gentle, safe, and empowering for both clients and clinicians. We'll talk about what makes psycholytic, or low-dose, ketamine different from traditional psychedelic experiences, how it can enhance the therapeutic process, and how you, as a therapist, can get trained to integrate it into your own work. This is one of those conversations that opens your mind to what's possible in therapy, so let's jump in. Resources Mentioned In This Episode Use the promo code "GORDON" to get 2 months of Therapy Notes free Consulting with Gordon The PsychCraft Network Profit First for Therapists Workbook Meet Sharon Niv, Ph.D. Dr. Sharon Niv is a cognitive psychologist and co-founder of Joyous Team, a Public Benefit Corporation dedicated to making evidence-based mental health treatments accessible and affordable. Her work bridges the worlds of neuroscience, technology, and therapy with a focus on how scalable, data-driven approaches can enhance emotional well-being. Dr. Niv earned her Ph.D. in Brain and Cognitive Science from the University of Southern California, where she conducted research on EEG biomarkers, neurofeedback, and the neural underpinnings of mood and behavior. She also holds a B.A. in Molecular and Cellular Biology from UC Berkeley and an M.A. in Clinical and Cognitive Psychology from USC. Before founding Joyous, Sharon worked on developing virtual-reality interventions for chronic pain and neurofeedback programs designed to help people improve emotional regulation and resilience. A long-time meditation practitioner, she combines scientific rigor with a deep understanding of mindfulness and experiential learning. Through Joyous, Sharon and her team are pioneering low-dose (psycholytic) ketamine therapy, creating safer, more sustainable pathways for individuals and therapists to experience healing and insight. Her mission is to empower both clinicians and clients with practical tools that promote neuroplasticity, compassion, and mental clarity. The Power of Therapy + Joyous Joyous Substack LinkedIn

Broadcast from KSQD, Santa Cruz on 10-09-2025: Dr. Dawn opens by addressing an emailer's question about safety of low-dose lithium for dementia prevention. She reports finding a two-year double-blind placebo-controlled trial of 61 patients with mild cognitive impairment that showed no kidney damage from therapeutic lithium doses. While low-dose lithium at 2-3 milligrams daily appears safe compared to therapeutic doses of 50-100 milligrams, she notes its calming effects may improve cognition. >/li> She discusses over-the-counter hearing aids now available without prescription, ranging from $98 to $999, representing significant savings compared to prescription models costing four times as much. >/li> An emailer asks about long-term methotrexate use for psoriasis, reporting declining white blood cell counts and slower healing. Dr. Dawn reviews studies showing that in 13-year rheumatoid arthritis trials, severe side effects occurred in only 3% of patients. She recommends monthly blood monitoring including comprehensive metabolic panels to check liver and kidney function. As an alternative, she suggests apremilast, which showed excellent long-term safety in pooled data from half a million patient years with virtually no liver, kidney, or blood count problems. She also recommends trying phototherapy with tuned red light frequencies and topical treatments before considering drugs like etanercept that carry leukemia and lymphoma risks. >/li> Dr. Dawn expands on ultra-processed food dangers, explaining how mechanical processing of carbohydrates accelerates digestion and causes blood sugar spikes that lead to insulin resistance. Steel-cut oatmeal and wheat berries digest slowly and accelerate glucose at a low rate, while instant oatmeal and white bread hit like loud spikes. She emphasizes that processing primarily affects carbohydrates, not proteins or fats. Whole fruits are vastly superior to juices because juicing makes fruit sugars unnaturally available to metabolism. She also warns about hidden microplastics entering food through processing equipment, transport tanks, and packaging, with longer processing and travel distances increasing contamination. >/li> Dr.Dawn discusses the health dangers of sedentary behavior, noting that simply walking 20 minutes daily can lower blood pressure without requiring intense exertion. Dr. Dawn offers creative exercise solutions including bouncing on inflatable exercise balls during screen time, keeping weights in bathrooms for tooth-brushing workouts or in other frequently used spaces, doing resistance band exercises while waiting in cars, and practicing single-leg squats for balance. She describes the geriatric "get up and go" test where inability to stand, walk 10 feet, return, and sit within 10 seconds predicts five-year mortality. >/li> A caller discusses motivation challenges with his unused NordicTrack equipment. Dr. Dawn suggests making exercise rewarding by listening to engaging podcasts exclusively during workouts, creating positive associations that build sustainable habits. She explains that five minutes daily for six days weekly, maintained for a month, typically becomes permanent. The caller correctly notes that exercise increases mitochondrial production, and Dr. Dawn expands on this, explaining how oxygen debt triggers DNA signals to build new muscle fibers and mitochondria, raising metabolic rate, improving glucose metabolism, and increasing brain-derived neurotrophic factor that promotes new neural connections, making exercise crucial for preventing cognitive decline. >/li>

Thoracic radiologists Jeffrey Kanne, Miranda Siemienowicz and Jonathan Chung discuss the current global status of lung cancer screening, offering tips and tricks for reading these studies. Meanwhile, Andrew and Frank talk about everything BUT pulmonary nodules: another shameful journal travesty, TB sniffer rats and ketamine epiphanies.   Lung cancer screening article ► https://radiopaedia.org/articles/lung-cancer-screening Retraction Watch - Tin Man Syndrome ► https://retractionwatch.com/2025/08/15/tin-man-syndrome-case-plagiarized-from-hoax-sleuths-say/ Those TB detecting rats ► https://apopo.org/what-we-do/detecting-tuberculosis Become a supporter ► https://radiopaedia.org/supporters Get an All-Access Pass ► https://radiopaedia.org/courses/all-access-course-pass Radiopaedia Community chat ► http://radiopaedia.org/chat Ideas and Feedback ► podcast@radiopaedia.org   The Reading Room is a radiology podcast intended primarily for radiologists, radiology registrars and residents. 

Low Dose is a specially-curated segment that combines the most interesting RHJ stories into one, bite-sized episode. Bypass all the fluff and get straight to the information you need to know. This week, we highlight the scientifically-backed strategies for manifesting your dream life, how the fashion industry is poisoning you, and a very real future where parents can design their own perfect baby. You can find more information about our guests and where to find each full episode below: 00:00-03:55 - The science to manifesting your dream life (Manifestation: Dr. James R. Doty ⁠⁠https://radiohealthjournal.org/manifestation-the-scientific-path-to-creating-your-dream-life/) 04:00-07:00 - How your clothes are poisoning you (Toxic Fashion: Alden Wicker ⁠https://radiohealthjournal.org/mercury-hats-arsenic-dresses-and-poisoned-shoes-toxic-fashion/) 07:00-10:00 - The future of genetically-modified humans. (Gene Editing: Dr. Elizabeth McNally https://radiohealthjournal.org/genomics-pt-2-designer-babies-illegal-experiments-and-moral-issues/) Learn more about your ad choices. Visit megaphone.fm/adchoices

In this powerful episode of the TIck Boot Camp Podcast, Dr. Jaquel Patterson, nationally recognized naturopathic physician and medical director of Fairfield Family Health, joins Matt Sabatello to explore the many layers of Lyme disease recovery – from hidden mold exposure to hormone balance and mental health support. Mold & Lyme Disease – Why mold toxicity can block Lyme recovery and how Dr. Patterson stages treatment so patients don't get overwhelmed. Hormone Health – The vital role hormones play in energy, mood, joint health, and the ability to fight chronic infections. Mental Health & Lyme – How inflammation impacts the brain, leading to panic attacks, anxiety, depression, and brain fog — and how those symptoms can reverse with healing. Low Dose Immunotherapy (LDI) – What it is, how it retrains the immune system to stop overreacting, and why it's helping Lyme patients stabilize. Inflammation & Flares – Practical tools like turmeric, hydration, and electrolytes to calm Herxheimer reactions and ease painful flare days. Environmental Toxins – How pesticides, polluted air, and contaminated water add to the burden — and realistic steps to reduce exposure.

FMF YouTube: https://www.youtube.com/@funmedFMI Center for Optimal HealthWebsite: fmioptimal.comInstagram: @fmioptimalFunctional Medicine of Idaho:Website: funmedidaho.comInstagram: @funmedidahoWe provide the highest quality supplements with responsible sourcing and the utmost commitment to purity funmedshop.com + more resources on IG: @funmedfoundations

Show notes at pharmacyjoe.com/episode1026. In this episode, I’ll discuss hallucinations from low-dose ketamine use in the ICU. The post 1026: Is the Low-Dose Ketamine In the Room With Us Right Now? appeared first on Pharmacy Joe.

Our bodies are exposed to about 20,000 hits of radiation from cosmic rays every second. Is that good or bad?

In episode 59 we discuss outpatient low-dose initiation of buprenorphine. Suen LW, Chiang AY, Jones BLH, Soran CS, Geier M, Snyder HR, Neuhaus J, Myers JJ, Knight KR, Bazazi AR, Coffin PO.Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl. JAMA Netw Open. 2025 Jan 2;8(1):e2456253. We also discuss impulse control dysregulation from ropinerole, and the new non-opioid painkiller, suzetrigine. BBC:Prescription medication made me a gambling addict Grall-Bronnec M, et al.Dopamine agonists and impulse control disorders: a complex association. Drug Saf. 2018;41(1):19-75. FDA:FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain Vertex Pharmaceuticals: Randomized, Placebo-Controlled, Phase 3 Trials of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor for Treatment of Acute Pain After Abdominoplasty or Bunionectomy --- This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go tothis link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, visitMI CARES. CME:https://micaresed.org/courses/podcast-addiction-medicine-journal-club/ --- Original theme music:composed and performed by Benjamin Kennedy Audio editing: Michael Bonanno Executive producer:Dr. Patrick Beeman A podcast fromArs Longa Media --- Learn more about your ad choices. Visit megaphone.fm/adchoices

DNS Podcast Dave Crosland & Scott McNally 0:00 teaser 0:30 Intro and advertisers 1:45 Lots of Yawns today 2:20 Will Tariffs Impact Gear? 7:20 what sources are saying 16:25 Varying opinions on Low Dose 19:00 Have cycle expectations changed? 23:20 Should we block DHT on cycle? 28:15 Synthoil Comment 29:45 How long on TRT between blasts 33:00 Tips to break a Plateau 42:50 No Changes in weight or strength on anadrol? 45:30 Do we count ester weight when designing a cycle 49:30 l-carnatine and improved sperm 53:45 High Estrogen and Acne 57:30 Uncle Dave's Wisdom 1:03:15 Uncle Dave's Wisdom Bonus 1:06:00 Dave's App (linked below)

In this solo episode, I'm breaking down one of the most talked-about tools in the health optimization world right now—peptides. From healing faster to building lean muscle, improving fat loss, enhancing sleep, and even slowing down the aging process… peptides are powerful. But they're also misunderstood, under-regulated, and often misused. So in this episode, I'm walking you through exactly what peptides are, how they work, the most popular ones in each category, and both the pros and cons of using them. This is a no-BS, educational breakdown of everything you need to know before exploring peptides as a tool for better health, performance, or aesthetics. I also cover some legal and sourcing realities—because here's the truth: most peptides aren't FDA-approved, and you'll only find them labeled for “research purposes only.” This isn't an endorsement. It's a breakdown to help you make smarter, more informed decisions.   What I Cover in This Episode: What peptides are and how they're different from hormones or steroids Legal disclaimers and how they're commonly sourced Growth hormone peptides: CJC-1295, Ipamorelin, MK-677 Fat loss peptides: AOD 9604 and Tesamorelin Healing peptides: BPC-157 and TB-500 Anti-aging + cognitive peptides: GHK-Cu (Copper peptide), Epitalon, Semax, Selank Mitochondrial optimizer: MOTS-c and why it's a game-changer for metabolic health How to stack peptides and what to avoid Side effects, risks, and what to consider before diving in   Links & References: Biological Activities and Safety of Citrus spp. Essential Oils - Click Here Essential role of TRPC6 channels in G2/M phase transition and development of human glioma - Click Here   Final Take: Peptides can be a powerful tool—but they're not a magic bullet. If you're training hard, eating right, sleeping well, and want to push to the next level, they might offer that extra edge. Just make sure you're doing it smart, and not chasing shortcuts.   Register For 30-Strong - Register Here   Join The Collective - Join Here   Interested in working with a coach? Get a free nutrition consultation - Schedule Here   Join Us On Patreon - Join Here   Submit your questions to be featured on our Q&A episodes.   Order from Cured Supplement Order from Legion Supplements and get 20% off your first order by using discount code: keynutrition   Connect with us on Instagram Host Brad Jensen – @thesoberbodybuilder Next Level Nutrition – @mynextlevelnutrition   Episode Timestamps 00:00 "Peptides: Unapproved but Legally Sold" 04:38 Compounding vs. Big Pharma Conflict 07:44 Benefits of Growth Hormone 13:31 MK677's Effects on Body Composition 16:51 Water Retention from Low Dose? 18:30 Health Supplement: Benefits and Considerations 23:35 "GLP1s and Peptide Therapy Debate" 27:03 GHK-CU: Skin and Anti-Aging Benefits 28:14 Copper Peptides for Hair and Healing 32:39 Growth Hormones and Water Retention 34:41 Success with BPC and TB500 40:13 GLP1s Fat Loss: Efficacy Concerns 42:03 "Peptides vs. Steroids: Health Debate" 45:11 "Join the Daily Wellness Movement"

Whats the lowest effective dose of tren? Well, We are going to find out lol. Plus my experinece loading carbs on GLP-1 meds like retatrutide or semaglutide. DADA = Massive Endurance PLUS your listner questions! ✅ Coach Scott McNally hangs with you guys and talks shop. Reach out for coaching or show sponorship at : mcnallydiets@gmail.com

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Sanjay Mehta is a radiation oncologist with over 25 years of experience, and is currently the president of Century Cancer Centers in Houston, Texas (drsanjaymehta.com). In this episode, Sanjay explores the rapidly evolving field of radiation oncology, addressing common misconceptions about radiation exposure. He delves into radiation's critical role in modern oncology, examining recent advancements that precisely target tumors while minimizing damage to surrounding healthy tissues and reducing side effects, with specific insights into breast, prostate, and brain cancers. Sanjay discusses fascinating international practices involving low-dose radiation therapy for inflammatory conditions such as arthritis, tendonitis, and sports injuries, highlighting its effectiveness and potential for wider adoption in the United States. Wrapping up on a lighter note, Peter and Sanjay discuss their mutual passion for cars and reveal how this shared interest first brought them together. We discuss: How radiation oncology became a distinct, rapidly evolving medical specialty [2:45]; Defining radiation, ionizing vs. non-ionizing, and common misconceptions about radiation exposure [5:30]; How radiation doses are measured, real-world examples of radiation exposure, and safety practices [9:00]; Radiation doses from common medical imaging tests, and why benefits of routine imaging outweigh risks [14:15]; Therapeutic radiation oncology: the evolution of breast cancer treatment toward less invasive surgery combined with targeted radiation [23:30]; Modern radiation oncology treatments for breast cancer—minimizing risks and maximizing patient comfort and outcomes [27:15]; How advances in radiation dosing, technology, and treatment precision have significantly reduced side effects [39:45]; How breast implants affect radiation treatment [44:45]; Radiation therapy for prostate cancer: advancements in precision, effectiveness, and patient selection criteria [48:00]; Radiation therapy options for inoperable prostate cancer or those seeking alternatives to surgery, and a remarkable patient case study [55:15]; How patients can effectively evaluate and select a high-quality radiation oncologist [1:05:45]; Radiation therapy for brain cancer: the shift toward precise, targeted techniques that minimize cognitive side effects, and remaining challenges [1:08:30]; The origins of radiophobia and how it influenced perceptions of radiation use in medicine [1:18:00]; Treating chronic inflammatory conditions such as tendinitis, arthritis, and more with very low-dose radiation [1:23:45]; Using low-dose radiation to treat spine injuries, scar tissue, fibrosis, keloids, and more [1:30:00]; The current barriers preventing widespread adoption of low-dose radiation therapy for inflammatory conditions [1:35:45]; The durability and versatility of low-dose radiation therapy in treating chronic inflammatory and arthritic conditions [1:40:45]; Sanjay's talent as a drummer [1:44:45]; Peter and Sanjay's shared passion for cars and racing [1:47:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

DNS Podcast 261 Dave Crosland & Scott McNally 00:00 Detroit Pro Recap and Competitor Insights 05:41 Exploring Low Dose Steroid Cycles 22:04 Listener Questions and Personal Experiences 27:20 The Evolution of Anabolic Steroids 31:12 Anadrol and Cutting Cycles 35:30 Navigating the End of the World: An Effort Stack 40:17 Sperm Quality and Testosterone Therapy 45:22 Aromatase Inhibitors: When to Stop? 50:04 Stress Management and Productivity ✅ Amino Asylum code THINK for 20% off research chems, peptides, l-carnitine and more https://aminoasylum.shop/ref/122/ ✅ Parabolic Peptides Code THINK for 10% off SLU, Research Chems, Peptides & more https://parabolicpeptides.com

Have you ever wondered what being high actually feels like, especially with low-dose cannabis? In this episode, Ellen and innovation & strategy expert Nicole Brown break down the future of socializing with cannabis, alcohol, and non-alcoholic drinks. If you've ever wished for a more predictable, enjoyable, and easy-to-access cannabis experience, this episode will get you excited about what's next. Nicole shares:  Why she believes we're living in Cannabis 2.0 How access to hemp-derived products is changing the game What she tells her friends who are curious about trying low-dose THC. If you enjoyed this episode, we recommend Episode 274. If You Like Chardonnay, Try A Weed Drink, Part 3 Hosted by Ellen Scanlon Sign up for Ellen's newsletter on Substack at https://dothepot.substack.com/ or at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠dothepot.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Thank you for supporting our sponsor! Try Potli's Dream Good Night Chews, and use code DOTHEPOT for 20% off Follow on IG: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@dothepot⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / FB: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@dothepot⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@dothepot⁠⁠⁠

We are delighted to partner with Western Radiation Oncology today, with two of their distinguished radiation oncologists joining us on the Prostate Health Podcast.  LDR (Low Dose Rate) prostate brachytherapy has recently been an underutilized treatment for prostate cancer. However, advancements in modern techniques have demonstrated that LDR brachytherapy, a procedure that can be performed quite easily in an ambulatory surgery center, offers high cure rates with minimal long-term complications, making it a convenient, non-invasive option for men with prostate cancer. Today, we chat with Dr. Steven Kurtzman and Dr. Ankit Agarwal, two distinguished radiation oncologists working to expand access to LDR brachytherapy by partnering with urologists to establish new programs across the United States.  Drs. Kurtzman and Agarwal are national leaders in targeted real-time intraoperative planned brachytherapy. With over 7,000 implants performed in the past two decades and more than 700 procedures conducted annually, they have managed to preserve this specialized technique despite its limited expansion in recent years. Based primarily in the Bay Area, California, they provide exceptional cancer care while collaborating with urologists, medical oncologists, and prostate cancer specialists across the United States to assist in establishing LDR programs in ambulatory surgery centers nationwide to provide high-quality prostate cancer care. Tune in to learn more about this promising treatment option! Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation. Show Highlights: Who are the most viable candidates for LDR brachytherapy? How the treatments for low, intermediate, and high-risk prostate cancer patients differ The benefits of a combination of brachytherapy and external beam radiation for high-risk prostate cancer patients How factors like urinary function, bowel function, and prostate size can influence men's eligibility for LDR brachytherapy Why prostate size is no longer a limitation for brachytherapy treatment How is the LDR brachytherapy procedure performed? What can patients expect in terms of recovery and side effects following brachytherapy? Post-therapy safety precautions Links:  Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd  Get your free What To Expect Guide (or find the link on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on Twitter and Instagram  Go to the Prostate Health Academy to sign up.  You can access Dr. Pohlman's free mini webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here. Sponsor Links:  Western Radiation Oncology Brachytherapy for Prostate Cancer with Dr. Steven Kurtzman and Dr. Ankit Agarwal on YouTube Expanding Treatment Options at Ambulatory Surgical Centers: LDR Brachytherapy for Prostate Cancer    

Dr. Dustin Jones // #GeriOnICE // www.ptonice.com  In today's episode of the PT on ICE Daily Show, join Modern Management of the Older Adult division leader Dustin Jones discusses the concept of "stronger with less," focusing on low dose training for older adults. He highlights a recent publication that challenges traditional biases regarding the dosage needed to elicit a positive response in older adults. Dustin aims to provide hope and practical insights for healthcare professionals, particularly those with limited interaction time with patients. He emphasizes the gap between recommended physical activity guidelines—such as 150 minutes of vigorous activity or 300 minutes of moderate activity weekly, along with resistance training—and the reality that many older adults, as well as healthcare providers, struggle to meet these standards. Dustin addresses the tension that arises when considering effective interventions that may fall short of conventional expectations, particularly in settings like home health and skilled nursing facilities. Take a listen to learn how to better serve this population of patients & athletes, or check out the full show notes on our blog at www.ptonice.com/blog. If you're looking to learn more about live courses designed to better serve older adults in physical therapy or our online physical therapy courses, check our entire list of continuing education courses for physical therapy including our physical therapy certifications by checking out our website. Don't forget about all of our FREE eBooks, prebuilt workshops, free CEUs, and other physical therapy continuing education on our Resources tab.

Show notes at pharmacyjoe.com/episode1002. In this episode, I’ll discuss some possible negative effects of using low-dose ketamine to achieve an opioid-sparing effect in critically ill patients. The post 1002: Less Opioid Consumption With Low-Dose Ketamine But at What Cost? appeared first on Pharmacy Joe.

As 2024 comes to an end, I'm rounding up some of the best gut health research and advice from the past year! In this compilation video, I'll share some of the best gut supplement recommendations as given by great expert guests – Dr. Allison Siebecker, Herbalist Olivia Amitrano, Dr. Alex Ford, Dr. Josh Axe, and Nutritional Therapist Elliot Overton. You don't want to miss this! Watch full interviews with each expert below.  

Welcome back to our weekend Cabral HouseCall shows! This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track! Check out today's questions:    Stacey: Hi Dr.Cabral , what is your opinion on low dose Ketamine? I know you spoke of it briefly a year or so ago but on not daily low dose, and at that time you were still researching between Ketamine and Psilocybin. What have your findings been ? I'm considering trying low dose ketamine for SEVERE Sensory overload, anxiety & now depression because it's robbing my life . I've been working on root cause , doing protocols, detoxes ect and have improved a lot but that just won't leave and by far the most worst of my symptoms. I tried SSRIs and my body does not like them at all , on Xanax now just to barely function and refuse to go up in dose per my Dr. wanting me to increase dose to help . Hoping your research can help my decision. I'm in CA and I don't think psilocybin is legal here yet .   Audrey: Hi Dr. Cabral, I try to avoid plastics whenever possible but sometimes they are hard to avoid. What about local honey at the farmers market that comes in a plastic bottle? Or drinking chilled water out of a plastic insulated thermos? I know leaching is terrible when the plastic is heated, but curious if the plastic doesn't get hot if it is just as bad. thanks   Anonymous: I tested positive for an STD called Ureaplasma, which is know to cause PID and infertility. I've taken many rounds of antibiotics and it has not gone away. I am also experiencing mild symptoms of urethritis which this is known to cause. I was wondering if there is any natural treatment for STDs or urethritis. I am also wondering if taking biofilms with the next round of antibiotics could help the antibiotics work better?   Sara: Hi Dr. Cabral, I just read your article on alkalized water and was wondering if there is whole home filter you would recommend. I have a small filter under my house and need to replace it. I looked at the AquaTru under sink filter, which looks great, but is there a good option to have a whole house alkalized filter? Thanks! Sara   Cindy: First , thank you for your generosity in sharing your knowledge so freely! I'm always looking for safe alternatives for anti-aging/beauty products in lieu of injectables, etc. Are you familiar with Procell? Procell uses microchanning along with a topically applied serum. According to their website “Procell's Microchannel Delivery Serum contains bone marrow-derived growth factors in a hyaluronic acid suspension. Both of these elements are naturally-occurring in the human body. There are no human, animal, or plant cells, DNA, blood, or any other foreign substances. The product has been used safely and effectively for over a decade.” How does one determine the safety of a product like this? I value your opinion! Is Procell therapy safe? Is microchanneling safe?   Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions!    - - - Show Notes and Resources: StephenCabral.com/3179 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!